Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Selective Progesterone Receptor Modulators" patented technology

As a contribution, so-called Selective Progesterone Receptor Modulators (SPRMs) have been developed. They have been described as agents with mixed antagonistic and agonistic effects on progesterone receptors in a tissue specific manner, while minimizing interactions with other steroidal receptors.

Steroids derivatives as selective progesterone receptor modulators

The present invention is directed to novel steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
Owner:JANSSEN PHARMA NV

Sequential SPRM/ progestin treatment

The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered.
Owner:ABBOTT ENDOCRINE INC

Compositions and methods for treating dysfunctional uterine bleeding

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating dysfunctional uterine bleeding. The instant invention is also relevant to the treatment and / or prevention of anemia in patients with dysfunctional uterine bleeding. Compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.
Owner:APTALIS PHARMA

Solid dispersion of a selective modulator of the progesterone receptor

The subject of the present invention is a solid dispersion comprising an active ingredient selected from the group consisting of selective progesterone receptor modulators, metabolites thereof and mixtures thereof, and a pharmaceutically acceptable polymeric excipient. The invention also relates to a pharmaceutical composition comprising said solid dispersion and to the therapeutic uses thereof.
Owner:LAB HRA PHARMA SA

Ethylene derivative serving as selective estrogen receptor modulators (SERMs)

The invention provides an ethylene derivative represented by a formula I. Serving as selective estrogen receptor modulators (SERMs), the ethylene derivative can be used for preventing and / or treating diseases or disease symptoms influenced by selective estrogen receptor modulation. The formula I is shown in the specifications.
Owner:CENTAURUS BIOPHARMA

Co-micronisation product comprising a selective progesterone-receptor modulator

The subject of the present invention is a co-micronization product comprising: an active ingredient selected from the group consisting of selective progesterone receptor modulators, metabolites thereof and mixtures thereof, and an N-vinyl-2-pyrrolidone-based polymeric excipient. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof.
Owner:LAB HRA PHARMA SA

Selective progesterone receptor modulators (SPRM) and stabilized estrogen level in patient

The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg / mL to 85 pg / mL.
Owner:BAYER PHARMA AG

Copper intrauterine device

InactiveUS20150320766A1Inhibits motilityInhibits viabilityBiocideOrganic active ingredientsSide effectGynecology
The invention relates to a copper contraceptive intrauterine system (IUS) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, for reducing or preventing bleeding side effects.
Owner:LAB HRA PHARMA SA

Sequential SPRM/progestin treatment

The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered.
Owner:ABBOTT ENDOCRINE INC

Compositions and methods for suppressing endometrial proliferation

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and / or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.
Owner:APTALIS PHARMA

Oxa-steroids derivatives as selective progesterone receptor modulators

The present invention is directed to novel 7-oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
Owner:JANSSEN PHARMA NV

Solid dispersions of selective progesterone receptor modulators

The subject of the present invention is a solid dispersion comprising an active ingredient selected from selective progesterone receptor modulators, their metabolites and mixtures thereof and a pharmaceutically acceptable polymeric excipient. The invention also relates to pharmaceutical compositions comprising said solid dispersions and their therapeutic use.
Owner:LAB HRA PHARMA SA

Selective progesterone receptor modulator (SPRM) regimen

InactiveCN107635562AOrganic active ingredientsSteroidsProgestin AntagonistRegimen
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11beta,17beta)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and / or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and / or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).
Owner:BAYER PHARMA AG

Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent

The subject matter of the present invention is pertinent to the field of oral delivery of pharmaceutically active agents. Embodiments of the instant invention disclose a liquid or semi-solid non-aqueous oral pharmaceutical fill composition comprising (a) a pharmaceutically effective amount of an unmicronized selective progesterone receptor modulator (SPRM) and (b) a polyethylene glycol (PEG) as well as methods for treating a variety of progesterone related disorders by orally administering such a composition.
Owner:APTALIS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products